Compare RELY & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELY | APLS |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.7B |
| IPO Year | 2021 | 2017 |
| Metric | RELY | APLS |
|---|---|---|
| Price | $14.53 | $24.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 19 |
| Target Price | $26.00 | ★ $33.11 |
| AVG Volume (30 Days) | ★ 3.7M | 2.2M |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.09 | ★ 0.36 |
| Revenue | ★ $1,544,865,000.00 | $1,016,397,000.00 |
| Revenue This Year | $30.78 | $29.00 |
| Revenue Next Year | $18.39 | N/A |
| P/E Ratio | $155.44 | ★ $70.45 |
| Revenue Growth | 31.27 | ★ 42.11 |
| 52 Week Low | $12.08 | $16.10 |
| 52 Week High | $27.32 | $35.71 |
| Indicator | RELY | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 56.06 | 62.55 |
| Support Level | $13.32 | $24.45 |
| Resistance Level | $15.77 | $25.52 |
| Average True Range (ATR) | 0.51 | 0.95 |
| MACD | 0.30 | 0.54 |
| Stochastic Oscillator | 62.50 | 81.70 |
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.